Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Chiron Begins Human Clinical Trials of Combination of Two HIV Vaccines

January 16, 2004

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Emeryville, Calif.-based biotechnology company Chiron on Thursday announced that it will begin human clinical trials of its experimental HIV vaccine, Bloomberg News/Los Angeles Times reports. Chiron, working with the HIV Vaccine Trials Network, a research effort supported by NIH, will administer the two-part injectable vaccine to 168 HIV-negative participants in the United States to determine if the vaccine is safe and if it strengthens the immune system (Bloomberg News/Los Angeles Times, 1/16). The trial first will be conducted at sites in St. Louis, Seattle and Nashville, Tenn., and later will be expanded to other HVTN sites, according to a Chiron release (Chiron release, 1/15). Over two years, participants will receive an injection of a DNA vaccine, which is based on the theory that two proteins from the DNA will prime the immune system for possible HIV infection. Participants will next receive an injection of a protein -- not DNA -- that will serve as a "booster" to the first injection, according to the Contra Costa Times. If the trial proves the two-step injection vaccine effective, Chiron plans to conduct a larger trial that would include hundreds of volunteers. Jorge Flores, head of the vaccine branch of NIAID's Division of AIDS, said, "We'll learn something, and that will help in designing vaccine for the next round (of trials)" (Silber, Contra Costa Times, 1/16).

Back to other news for January 16, 2004


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2003 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More Research on Vaccines for HIV Prevention
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement